 NEW YORK--BUSINESS WIRE--Schrödinger, Inc. Nasdaq: SDGR, whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62nd American Society of Hematology ASH Annual Meeting. MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1, is considered a potential therapeutic target for several non-Hodgkins B-cell lymphomas as w 